Please assess the completion status of the following clinical trial:

Trial Title: Letrozole Versus Clomifene Citrate for Ovulation Induction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age: 18 - 39~2. BMI \< 36~3. Infertility due to anovulation~4. PCOS: At least two of the following diagnostic criteria of:~   1. Oligo/amenorrhoea~  2. Hyperandrogenaemia: biochemical (testosterone ≥2.5 nmol/l or free androgen index (FAI) ≥ 5) or clinical (acne/hirsutism) evidence~  3. USS evidence of PCO (either ≥12 follicles measuring 2-9 mm in diameter, or an ovarian volume of \> 10 ml)~5. No recent (within 6 months) treatment for induction of ovulation~6. Normal semen analysis (WHO 1999)~7. Proven patency of at least one Fallopian tube~Exclusion Criteria:~1. Inability to give informed consent~2. Contraindication to letrozole or clomifene citrate~3. Absence of any inclusion criteria

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- Clomiphene citrate (Type: ACTIVE_COMPARATOR): Starting daily dose 50 mg on menstrual cycles days 2 to 6, to be increased to 100 mg daily if there is no response to 50 mg
- Letrozole (Type: ACTIVE_COMPARATOR): Starting daily dose 2.5 mg on menstrual cycles days 2 to 6, to be increased to 5 mg daily if there is no response to 2.5 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).